XM does not provide services to residents of the United States of America.
S
S

Sanofi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Probiotics maker Seed Health explores $1 billion sale, sources say

Probiotics maker Seed Health explores $1 billion sale, sources say By Abigail Summerville and Anirban Sen June 12 (Reuters) - The owners of Seed Health, one of the few profitable U.S. biotechnology startups, are exploring a sale of the probiotics maker that could value it at more than $1 billion, according to people familiar with the matter. Seed, which is owned by its founders and co-chief executives Ara Katz and Raja Dhir, as well as venture capital investors, is soliciting acquisition offers
S

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

UPDATE 1-GSK asks to appeal Delaware ruling allowing Zantac cases to go forward Recasts headline, paragraphs 1-4 with appeal petition By Brendan Pierson June 10 (Reuters) - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
G
P
S

Latest trial over Zantac cancer claims called off as plaintiff drops case

Latest trial over Zantac cancer claims called off as plaintiff drops case By Brendan Pierson June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's GSK.L discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced. GSK said in a statement that it did not settle with the woman, Eugenia Kasza.
G
P
S

Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial

BUZZ-Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial ** Shares of Moderna MRNA.O rise 1.81% to $153.75 premarket ** Co says its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response when compared to separate shots in a late-stage trial ** The combination vacci
G
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.